Biomarker‐driven phenotyping in Parkinson's disease: A translational missing link in disease‐modifying clinical trials

ABSTRACT Past clinical trials of putative neuroprotective therapies have targeted PD as a single pathogenic disease entity. From an Oslerian clinicopathological perspective, the wide complexity of PD converges into Lewy bodies and justifies a reductionist approach to PD: A single‐mechanism therapy c...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Movement disorders 2017-03, Vol.32 (3), p.319-324
Hauptverfasser:	Espay, Alberto J., Schwarzschild, Michael A., Tanner, Caroline M., Fernandez, Hubert H., Simon, David K., Leverenz, James B., Merola, Aristide, Chen‐Plotkin, Alice, Brundin, Patrik, Kauffman, Marcelo A., Erro, Roberto, Kieburtz, Karl, Woo, Daniel, Macklin, Eric A., Standaert, David G., Lang, Anthony E.
Format:	Artikel
Sprache:	eng
Schlagworte:	Biomarkers Clinical trials Clinical Trials as Topic Dopamine Humans Lewy bodies Movement disorders Neurodegeneration Neurodegenerative diseases Neuroprotection Parkinson Disease - classification Parkinson Disease - diagnosis Parkinson Disease - therapy Parkinson's disease Phenotypes Phenotyping Precision medicine Substantia nigra systems biology
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!